Antibe Therapeutics Inc(Pre-Merger) ATBPF

RE:RE:RE:RE:McWhirter Link

[RalphRalph]

McWhirter's opinion about a current $600 million valuation seems reasonable to me.   I don't believe he said that's what it would or should fetch in a buyout; just that that number was a reasonable valuation given where Antibe is in the development process.  I doubt that any big Pharma would currently offer Antibe (with a $125 million market cap) a $1 billion+ buyout offer.  

I suspect the problems of past NSAIDs  are to some extent being held against Antibe as well. Most potential investors aren't looking closely enough to see that the problematic NSAIDs of the past were cox-2 inhibitors and that Antibe offers a much differentiated product.   I suspect that they are especially hesitant to embrace a new next-generation NSAID given the hype & failures that have occurred in the past.   

Antibe is going to have to "prove it", so to speak, through acquisition of a major Pharma partnership and successful Phase 3 results.   A partnership with a big Pharma company would be particularly validating.  Even though they raised capital recently, they still don't have funding  necessary to complete Phase 3.  That overhang needs to be resolved before significant progress can be made.  

That's likely a big part of the reason for the company seeming so undervalued compared to earnings potential.   Being OTC in the U.S. also likely contributes to the company being overlooked and seemingly undervalued.

bringon10bagger wrote: He didn't even convey the point of partnering with big pharma for phsse 3, huge miss on his part........imo still a holder and loading up at these levels....and what a stupid comment to say with phase 2 complete would fetch 600M.....all relevant to how big the prize is and ATE's case........HUGE prize, BEST in CLASS NSAID's multibillion payback